We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




MRI Technology Enables Noninvasive Monitoring of Emergent Cell Therapies

By LabMedica International staff writers
Posted on 07 Oct 2014
Print article
Cellular therapeutics, the application of using intact cells to treat and cure disease, is an important potential new therapeutic application, but it is hampered by the inability of clinicians and scientists to effectively monitor the destination, movements, and perseverance of these cells in patients without having to use invasive procedures, such as tissue sampling.

In a study published September 19, 2014, in the online journal Magnetic Resonance in Medicine, researchers from the University of California (UC), San Diego School of Medicine (USA), University of Pittsburgh, and elsewhere describe the first human tests of using a perfluorocarbon (PFC) tracer in combination with noninvasive magnetic resonance imaging (MRI) scanning to track therapeutic immune cells injected into colorectal cancer patients.

“Initially, we see this technique used for clinical trials that involve tests of new cell therapies,” said first author Eric T. Ahrens, PhD, professor in the department of radiology at UC San Diego. “Clinical development of cell therapies can be accelerated by providing feedback regarding cell motility, optimal delivery routes, individual therapeutic doses, and engraftment success.”

Currently, there is no accepted way to image cells in the human body that includes a broad range of cell types and diseases. Earlier strategies have employed metal ion-based vascular MRI contrast agents and radioisotopes. The former have been shown to be difficult to differentiate in vivo; the latter raise apprehensions about radiation toxicity and do not provide the anatomic facets available with MRI scans. “This is the first human PFC cell tracking agent, which is a new way to do MRI cell tracking,” said Dr. Ahrens. “It’s the first example of a clinical MRI agent designed specifically for cell tracking.”

Researchers utilized a PFC tracer agent and an MRI technique that directly identifies fluorine atoms in labeled cells. Fluorine atoms naturally occur in extremely low concentrations in the body, making it easier to see cells labeled with fluorine using MRI scanning. In this instance, the engineered and labeled dendritic cells—powerful stimulators of the immune system—were first prepared from white blood cells extracted from the patient. The cells were then injected into patients with stage 4 metastatic colorectal cancer to trigger an anticancer T-cell immune response.

The published study did not evaluate the effectiveness of the cell therapy, but instead the ability of researchers to detect the labeled cells and monitor what occurred to them. Ahrens said the technique worked as expected, with the unanticipated finding that only half of the delivered cell vaccine remained at the inoculation site after 24 hours.

“The imaging agent technology has been to shown to be able to tag any cell type that is of interest,” Dr. Ahrens concluded. “It is a platform imaging technology for a wide range of diseases and applications, which might also speed development of relevant therapies. Noninvasive cell tracking may help lower regulatory barriers. For example, new stem cell therapies can be slow to obtain regulatory approvals in part because it is difficult, if not impossible, with current approaches to verify survival and location of transplanted cells. And cell therapy trials generally have a high cost per patient. Tools that allow the investigator to gain a ‘richer’ data set from individual patients mean it may be possible to reduce patient numbers enrolled in a trial, thus reducing total trial cost.”

Related Links:

University of California, San Diego School of Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.